JP4705783B2 - レセプターの脱感作の予防 - Google Patents

レセプターの脱感作の予防 Download PDF

Info

Publication number
JP4705783B2
JP4705783B2 JP2004548325A JP2004548325A JP4705783B2 JP 4705783 B2 JP4705783 B2 JP 4705783B2 JP 2004548325 A JP2004548325 A JP 2004548325A JP 2004548325 A JP2004548325 A JP 2004548325A JP 4705783 B2 JP4705783 B2 JP 4705783B2
Authority
JP
Japan
Prior art keywords
receptor
donor
gsno
nitric oxide
nitrosoglutathione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004548325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503901A (ja
JP2006503901A5 (https=
Inventor
ジョナサン エス． ステイムラー，
ロバート ジェイ． レフコウィッツ，
エリン ジェイ． ワーレン，
ウォルター ジェイ． コッホ，
クラウド エー． ピアンタドシ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2006503901A publication Critical patent/JP2006503901A/ja
Publication of JP2006503901A5 publication Critical patent/JP2006503901A5/ja
Application granted granted Critical
Publication of JP4705783B2 publication Critical patent/JP4705783B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004548325A 2002-10-25 2003-10-20 レセプターの脱感作の予防 Expired - Fee Related JP4705783B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/280,085 US6627602B2 (en) 2001-11-13 2002-10-25 Preventing desensitization of receptors
US10/280,085 2002-10-25
PCT/US2003/029134 WO2004039313A2 (en) 2002-10-25 2003-10-20 Preventing desensitization of receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010101547A Division JP2010159307A (ja) 2002-10-25 2010-04-26 レセプターの脱感作の予防

Publications (3)

Publication Number Publication Date
JP2006503901A JP2006503901A (ja) 2006-02-02
JP2006503901A5 JP2006503901A5 (https=) 2006-11-09
JP4705783B2 true JP4705783B2 (ja) 2011-06-22

Family

ID=32228743

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004548325A Expired - Fee Related JP4705783B2 (ja) 2002-10-25 2003-10-20 レセプターの脱感作の予防
JP2010101547A Withdrawn JP2010159307A (ja) 2002-10-25 2010-04-26 レセプターの脱感作の予防

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010101547A Withdrawn JP2010159307A (ja) 2002-10-25 2010-04-26 レセプターの脱感作の予防

Country Status (6)

Country Link
US (3) US6627602B2 (https=)
EP (1) EP1567182A4 (https=)
JP (2) JP4705783B2 (https=)
AU (1) AU2003287006B2 (https=)
CA (1) CA2503624A1 (https=)
WO (1) WO2004039313A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010159307A (ja) * 2002-10-25 2010-07-22 Duke Univ レセプターの脱感作の予防

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627738B2 (en) * 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
CA2425489C (en) * 2000-10-16 2011-05-17 Duke University Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
AU2002224466A1 (en) * 2000-10-31 2002-05-15 Duke University Hypotension
US20040110691A1 (en) * 2001-11-13 2004-06-10 Stamler Jonathan S. Thiol reactive agents as a therapeutic modality
GB0326047D0 (en) * 2003-11-07 2003-12-10 Univ Sheffield Substance
ES2543836T3 (es) * 2004-04-23 2015-08-24 Northern Sydney Local Health District Procedimientos y composiciones para el tratamiento de afecciones miocárdicas
ES2731298T3 (es) 2005-05-27 2019-11-14 Univ North Carolina Chapel Hill Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas
JP2008303145A (ja) * 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
FR2914554B1 (fr) * 2007-04-05 2009-07-17 Germitec Soc Par Actions Simpl Procede de suivi de l'uitilisation d'un appareil medical.
WO2010042546A1 (en) 2008-10-06 2010-04-15 Indiana University Research And Technology Corporation Methods and apparatus for active or passive assistance in the circulatory system
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
CA2771389C (en) 2009-08-21 2019-04-09 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
BR112012008508A2 (pt) * 2009-10-13 2017-06-13 Novan Inc revestimento de sol-gel, substrato, método para produzir um revestimento de sol-gel
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
HUE052023T2 (hu) * 2016-05-27 2021-04-28 Ipsen Biopharm Ltd Triptofánnal vagy tirozinnal stabilizált folyékony neurotoxin készítmény
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476108A (en) * 1981-01-16 1984-10-09 Kessler Jack H Bactericidal method
JPS63208525A (ja) * 1987-02-25 1988-08-30 Kikkoman Corp 心不全治療剤
WO1992010228A1 (en) * 1990-12-05 1992-06-25 The General Hospital Corporation Devices for treating pulmonary vasoconstriction and asthma
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6197745B1 (en) * 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US5985862A (en) * 1996-05-02 1999-11-16 G.D. Searle & Co. Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
EP1015490B1 (en) * 1997-02-06 2004-04-14 Duke University No-modified hemoglobins and uses therefor
WO1998043621A1 (en) * 1997-03-31 1998-10-08 The Children's Medical Center Corporation Nitrosylation to inactivate apoptotic enzymes
WO1998052580A1 (en) * 1997-05-21 1998-11-26 Duke University Treating asthma by preventing and/or accommodating for s-nitrosothiol breakdown
US6486206B1 (en) * 1997-09-29 2002-11-26 Cprx Inc. Mechanical and pharmacologic therapies to treat cardiac arrest
WO1999018949A1 (en) * 1997-10-15 1999-04-22 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
AU1770299A (en) 1997-12-23 1999-07-19 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
EP1126838A4 (en) * 1998-10-30 2005-02-16 Nitromed Inc NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
US7045152B2 (en) * 1999-09-08 2006-05-16 Duke University Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US6314956B1 (en) * 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
CA2410632A1 (en) * 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
CA2425489C (en) * 2000-10-16 2011-05-17 Duke University Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
US6359182B1 (en) 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US6489206B2 (en) * 2001-03-22 2002-12-03 United Microelectronics Corp. Method for forming self-aligned local-halo metal-oxide-semiconductor device
US6627602B2 (en) * 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
US6472390B1 (en) 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010159307A (ja) * 2002-10-25 2010-07-22 Duke Univ レセプターの脱感作の予防

Also Published As

Publication number Publication date
CA2503624A1 (en) 2004-05-13
EP1567182A4 (en) 2010-09-08
AU2003287006B2 (en) 2010-03-18
US6627602B2 (en) 2003-09-30
US20030092633A1 (en) 2003-05-15
JP2006503901A (ja) 2006-02-02
WO2004039313A2 (en) 2004-05-13
JP2010159307A (ja) 2010-07-22
AU2003287006A1 (en) 2004-05-25
WO2004039313A3 (en) 2004-07-22
EP1567182A2 (en) 2005-08-31
US20040053852A1 (en) 2004-03-18
US20060100159A1 (en) 2006-05-11
US6964984B2 (en) 2005-11-15

Similar Documents

Publication Publication Date Title
JP2010159307A (ja) レセプターの脱感作の予防
Xu et al. Efficacy and mechanism of cGAMP to suppress Alzheimer’s disease by elevating TREM2
JP5259038B2 (ja) 血圧または肺動脈圧を大きく低下させない一酸化窒素ドナーの治療的投薬量の使用
Zhang et al. Cerebral mast cells contribute to postoperative cognitive dysfunction by promoting blood brain barrier disruption
Torregroza et al. Perioperative cardioprotection: general mechanisms and pharmacological approaches
EP0998274B1 (en) Microdose therapy of vascular conditions by no donors
US8815297B2 (en) Modulation of beta 2 adrenergic receptors by inhibitors of EGLN3 or pVHL
JP2020524702A (ja) 免疫応答を調節するｇａｂａの能力の強化
Zhang et al. The role of janus kinase/signal transducer and activator of transcription signalling on preventing intestinal ischemia/reperfusion injury with dexmedetomidine
NO331674B1 (no) Farmasoytisk sammensetning omfattende nikotinreseptorantagonist for lindring eller forebygging av pulmonaer inflammatorisk sykdom
CA3112695A1 (en) Composition for treating fibrotic diseases, comprising benzhydryl thioacetamide compound as active ingredient
Ayatollahi et al. Effect of oral gabapentin on haemodynamic variables during microlaryngoscopic surgery
Kinoshita et al. Nurr1 overexpression in the primary motor cortex alleviates motor dysfunction induced by intracerebral hemorrhage in the striatum in mice
WO2021150598A1 (en) Affinity peptide conjugated with antioxidant for protection of proteins from oxidation
Wu et al. Controlled Hemorrhage Sensitizes Angiotensin II‐Elicited Hypertension Through Activation of the Brain Renin‐Angiotensin System Independently of Endoplasmic Reticulum Stress
Zhou et al. Aromadendrin protects mouse liver from sepsis-induced injury by inhibiting NF-κB signaling pathway
CN111278452A (zh) 以阿林肽为活性成分的尿毒症药物
US20160166577A1 (en) Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
JP7628237B2 (ja) 自己免疫疾患の予防及び／又は治療のための医薬組成物
KR20180015085A (ko) 신경퇴행성 질환의 예방 또는 치료를 위한 약제학적 조성물
WO2018057933A1 (en) Compounds, compositions, and methods for reducing oxidative stress in cardiomyocytes
JP7219476B2 (ja) 腱滑膜病変を主体とした疾患の治療薬
JP5011496B2 (ja) 脳梗塞抑制剤
JPH08508710A (ja) 新規処置方法
Adeoye Pearce (Loma Linda University School of Medicine, USA) Role of Sympathetic Perivascular Innervation in Cerebral Artery Remodeling during Chronic Hypoxia in Ovine Species Blood vessels have intrinsic ability to mount adaptive changes during hypoxic

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100323

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110105

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110314

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees